Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-2701 in advanced solid tumors
NCT02228811Phase 1Terminated
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of altiratinib in solid tumor (advanced stage) and metastatic solid tumors, sponsored by Deciphera Pharmaceuticals. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2014; status: terminated.
02
Drugs
altiratinib
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT02228811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228811.